Prothena Corp Public (PRTA) Other Non-Current Liabilities (2014 - 2022)
Prothena Corp Public (PRTA) posted quarterly Other Non-Current Liabilities of $553000.0 for Q4 2022, little changed year-over-year from $553000.0 in Q4 2021, and little changed quarter-over-quarter from $553000.0 in Q3 2022.
Prothena Corp Public (PRTA) Other Non-Current Liabilities (2014 - 2022) Analysis & Trends
Prothena Corp Public's Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $553000.0 for Q4 2022.
- In Q4 2022, Other Non-Current Liabilities changed 0.0% year-over-year to $553000.0; the TTM figure through Dec 2022 stood at $553000.0 (changed 0.0% YoY), while the FY2022 annual figure was $553000.0, changed 0.0% from the prior year.
- Other Non-Current Liabilities for Q4 2022 stood at $553000.0, roughly flat from $553000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $553000.0 in Q3 2018, with the low at $553000.0 in Q3 2018.
- The 5-year median for Other Non-Current Liabilities is $553000.0 (2018), against an average of $553000.0.
- Peak annual rise in Other Non-Current Liabilities reached 0.0% in 2019, while the deepest fall reached 0.0% in 2019.
- Prothena Corp Public's Other Non-Current Liabilities stood at $553000.0 in 2018, then changed by 0.0% to $553000.0 in 2019, then changed by 0.0% to $553000.0 in 2020, then changed by 0.0% to $553000.0 in 2021, then changed by 0.0% to $553000.0 in 2022.
- Business Quant data shows PRTA's Other Non-Current Liabilities at $553000.0 in Q4 2022, $553000.0 in Q3 2022, and $553000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Prothena Corp Public | 458.45 Mn | 170.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 553,000.00 |
| Sep 30, 2022 | 553,000.00 |
| Jun 30, 2022 | 553,000.00 |
| Mar 31, 2022 | 553,000.00 |
| Dec 31, 2021 | 553,000.00 |
| Sep 30, 2021 | 553,000.00 |
| Jun 30, 2021 | 553,000.00 |
| Mar 31, 2021 | 553,000.00 |
| Dec 31, 2020 | 553,000.00 |
| Sep 30, 2020 | 553,000.00 |
| Jun 30, 2020 | 553,000.00 |
| Mar 31, 2020 | 553,000.00 |
| Dec 31, 2019 | 553,000.00 |
| Sep 30, 2019 | 553,000.00 |
| Jun 30, 2019 | 553,000.00 |
| Mar 31, 2019 | 553,000.00 |
| Dec 31, 2018 | 553,000.00 |
| Sep 30, 2018 | 553,000.00 |
| Dec 31, 2016 | 98,000.00 |
| Jun 30, 2016 | 98,000.00 |